Zydus receives tentative approval for Topiramate tablets

Cadila Healthcare Ltd has announced that the Company has received tentative approval for Topiramate Tablets in the strengths of 25 mg, 50 mg, 100 mg and 200 mg from the USFDA. The branded sales of Topiramate Tablets, an anti-epileptic drug, which falls in the CNS segment, is estimated at USD 1.85 billion in 2006 as per NDC Health. It is scheduled to be launched in September 2008 upon patent expiry.

The group now has 24 approvals since the commencement of filing process in FY 2003-04. Currently the group markets 10 generics through its subsidiary Zydus Pharmaceuticals (USA) Inc.

The stock was trading at Rs.336.50, up by Rs.0.60 or 0.18%. The stock hit an intraday high of Rs.341 and low of Rs.333.10. The total traded quantity was 10446 compared to 2 week average of 12742.

Source : Equity Bulls

Keywords